---
title: "Saliva-based nanopore sequencing panel for pharmacogenomic screening in drug-resistant tuberculosis"
id: "medrxiv-5-nanopore-sequencing-panel-for-saliva-based-host-pharmacogenomic-screening-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-nanopore-sequencing-panel-for-saliva-based-host-pharmacogenomic-screening-in"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Saliva-based nanopore sequencing panel for pharmacogenomic screening in drug-resistant tuberculosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-nanopore-sequencing-panel-for-saliva-based-host-pharmacogenomic-screening-in
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors developed a **16-plex nanopore sequencing panel** targeting 23 host variants (21 clinically validated, 2 predicted actionable) that affect exposure and toxicity of second-line anti-tubercular drugs: **linezolid, bedaquiline, clofazimine, moxifloxacin, and ethambutol**. - The panel was benchmarked by sequencing 50 Coriell DNA samples (from the 1000 Genomes Project) and then applied to **saliva from 202 patients** receiving treatment for drug-resistant tuberculosis in India using a MinION Mk1C (R10.4) device. - Sequencing produced high depth in saliva with a reported median coverage of **3,609X**, and data were processed using in‑house analysis pipelines. - Pharmacokinetic and toxicity data were assessed alongside genotype. Several genotype–phenotype trends reached nominal significance in specific subgroups rather than across the entire cohort. - Among patients receiving **high-dose moxifloxacin (800 mg daily)**, the **UGT1A1 rs3755319 A>C** variant was associated with higher trough concentrations in heterozygotes and homozygous alternates compared with reference genotype. - For **linezolid**, among patients dose-reduced to **300 mg**, homozygous alternate **ABCB1 rs2032582 A>C** carriers (7/98) had significantly lower Cmin than wild-type and heterozygotes; these associations were not observed at standard dosing. - **Linezolid-associated toxicity** occurred more frequently in **ABCB1 rs1128503 A>G** heterozygotes versus homozygous reference (58.3% vs. 29.1%). - **UGT1A1 rs4148323 G>A** heterozygotes had higher rates of moxifloxacin toxicity than wild-type (42.9% vs. 14.3%). - The authors conclude portable, **saliva-based sequencing** reliably detects pharmacogenetic variants and could support pre-treatment screening to predict drug exposure or toxicity; specific clinical implementation details and broader validation needs were not reported in the source. - Ethical approvals were obtained from PD Hinduja Hospital (Mumbai), Johns Hopkins University, and the Institute of Bioinformatics (Bangalore). Funders included the Department of Biotechnology, Department of Science and Technology, and NIAID grants cited in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=0Xa0hsK0pCRZg.8n0OZPz3TPXBOoAZ1PrG70uHsYWMA-1788566870.324851-1.2.1.1-G2HEmZ185em1y7t5_0aXernx4yZbTwiBgH1DOwbzJNjAsfH_BpK.4rl6gEZvhVhM) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Nanopore sequencing panel for saliva-based host pharmacogenomic screening in anti-tubercular therapy Priyanka Yadav, Swarup A. V. Shah, Aishwarya S. Babu, Minal Paradkar, Shruthi Vasanthaiah, Karthick Vasudevan, Prerna R. Arora, Rohan V. Lokhande, Heeral U.B. Pandya, [ View ORCID Profile](http://orcid.org/0000-0001-7494-079X)Paolo Denti, Camilla Rodrigues, Jason R. Andrews, [ View ORCID Profile](http://orcid.org/0000-0001-9943-6127)Akhilesh Pandey, Jeffrey A Tornheim, Tester F. Ashavaid, Renu Verma doi: https://doi.org/10.64898/2026.09.02.26362034 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Priyanka Yadav 1 Institute of Bioinformatics, International Tech Park, Bangalore, Karnataka, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Priyanka%2BYadav%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yadav%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APriyanka%2BYadav%2B) Swarup A. V. Shah 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Swarup%2BA.%2BV.%2BShah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shah%20SA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASwarup%2BA.%2BV.%2BShah%2B) Aishwarya S. Babu 3 1. Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India 2. Institute of Bioinformatics, International Tech Park, Bangalore, Karnataka, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aishwarya%2BS.%2BBabu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Babu%20AS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAishwarya%2BS.%2BBabu%2B) Minal Paradkar 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Minal%2BParadkar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Paradkar%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMinal%2BParadkar%2B) Shruthi Vasanthaiah 3 1. Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India 2. Institute of Bioinformatics, International Tech Park, Bangalore, Karnataka, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shruthi%2BVasanthaiah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vasanthaiah%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShruthi%2BVasanthaiah%2B) Karthick Vasudevan 3 1. Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India 2. Institute of Bioinformatics, International Tech Park, Bangalore, Karnataka, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Karthick%2BVasudevan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vasudevan%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKarthick%2BVasudevan%2B) Prerna R. Arora 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Prerna%2BR.%2BArora%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Arora%20PR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APrerna%2BR.%2BArora%2B) Rohan V. Lokhande 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rohan%2BV.%2BLokhande%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lokhande%20RV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARohan%2BV.%2BLokhande%2B) Heeral U.B. Pandya 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Heeral%2BU.B.%2BPandya%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pandya%20HU&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHeeral%2BU.B.%2BPandya%2B) Paolo Denti 4 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paolo%2BDenti%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Denti%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaolo%2BDenti%2B) * [ORCID record for Paolo Denti](http://orcid.org/0000-0001-7494-079X "Open in new tab") Camilla Rodrigues 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Camilla%2BRodrigues%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rodrigues%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACamilla%2BRodrigues%2B) Jason R. Andrews 5 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, California, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jason%2B%2BR.%2BAndrews%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Andrews%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJason%2B%2BR.%2BAndrews%2B) Akhilesh Pandey 6 Department of Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Akhilesh%2BPandey%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pandey%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAkhilesh%2BPandey%2B) * [ORCID record for Akhilesh Pandey](http://orcid.org/0000-0001-9943-6127 "Open in new tab") Jeffrey A Tornheim 7 Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jeffrey%2BA%2BTornheim%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tornheim%20JA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJeffrey%2BA%2BTornheim%2B) Tester F. Ashavaid 2 PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tester%2BF.%2BAshavaid%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ashavaid%20TF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATester%2BF.%2BAshavaid%2B) Renu Verma 8 Institute of bioinformatics * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Renu%2BVerma%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Verma%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARenu%2BVerma%2B) * For correspondence: renuverma@ibioinformatics.org * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1292938/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1292938/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1292938/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1292938/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1292938/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1292938/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Abstract Rationale: Host genotypes can predict subtherapeutic anti-tubercular drug exposures and treatment-associated toxicities. Screening for these variants could enable personalized dosing, but scalable assays for second-line drugs are lacking. Objectives: We developed a nanopore sequencing panel to detect host variants affecting anti-tuberculosis drug troughs and toxicities, and evaluated its performance as a saliva-based screening tool. Methods: We designed a 16-plex panel targeting 23 variants (21 clinically validated, 2 predicted actionable) relevant to linezolid, bedaquiline, clofazimine, moxifloxacin, and ethambutol exposure. We first sequenced 50 Coriell DNA (1000 Genomes Project) to benchmark accuracy against Illumina, then sequenced saliva from 202 individuals treated for drug-resistant tuberculosis in India using MinION Mk1C (R10.4). Plasma trough concentrations and toxicity frequencies were stratified by genotype. Data were analyzed using in‑house pipelines. Measurements and Main Results: The panel showed high coverage in saliva (median 3,609X). Several suggestive genotype-phenotype trends reached nominal significance in distinct subsets. Among patients on high-dose moxifloxacin (800mg daily), UGT1A1 rs3755319 A>C was associated with higher troughs in heterozygotes (6/14, p C homozygous alternates (7/98) had significantly lower Cmin versus wild-type (p G heterozygotes versus homozygous reference (58.3% vs. 29.1%), and UGT1A1 rs4148323 G>A heterozygotes showed higher moxifloxacin toxicity rates than wild-type (42.9% vs. 14.3%). Conclusions: Portable, saliva-based sequencing reliably detects pharmacogenetic variants and could inform pre-treatment screening for drug exposure or toxicity. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was obtained from the ethics committee of PD Hinduja Hospital, Mumbai (IRB00012235), Johns Hopkins University (FWA00005752), and the Institute of Bioinformatics, Bangalore (EC/NEW/INST/2021/2463). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors ## Funder Information Declared Department of Biotechnology, https://ror.org/03tjsyq23, ID No. BT/HRD/35/02/2006, BT/PR24492/MED/29/1219/2017 Department of Science and Technology, https://ror.org/0101xrq71, DST/INT/SOUTH AFRICA/P-24/2017 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, R01AI168371, R01AI175618 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.01.26361120v1 "A Tunable Flat-Jet Hydro-Debridement Device: Clinical Feasibility for Soft Tissue Wound Management")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.31.26361636v1 "Rest-activity and circadian rhythm parameters relate to cognition and disability outcomes in multiple sclerosis") Posted September 04, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/04/2026.09.02.26362034.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.02.26362034v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/04/2026.09.02.26362034.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Nanopore sequencing panel for saliva-based host pharmacogenomic screening in anti-tubercular therapy Priyanka Yadav, Swarup A. V. Shah, Aishwarya S. Babu, Minal Paradkar, Shruthi Vasanthaiah, Karthick Vasudevan, Prerna R. Arora, Rohan V. Lokhande, Heeral U.B. Pandya, Paolo Denti, Camilla Rodrigues, Jason R. Andrews, Akhilesh Pandey, Jeffrey A Tornheim, Tester F. Ashavaid, Renu Verma medRxiv 2026.09.02.26362034; doi: https://doi.org/10.64898/2026.09.02.26362034 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362034v1%26text%3DNanopore%2520sequencing%2520panel%2520for%2520saliva-based%2520host%2520pharmacogenomic%2520screening%2520in%2520anti-tubercular%2520therapy "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.02.26362034v1%26t%3DNanopore%2520sequencing%2520panel%2520for%2520saliva-based%2520host%2520pharmacogenomic%2520screening%2520in%2520anti-tubercular%2520therapy "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.6
## Related Clinical Research

- [Association of Linezolid Interruption and Rechallenge With Outcomes in Rifampicin-Resistant TB,](https://medichelpline.com/clinical-feed/the-lancet-global-health-21-association-of-linezolid-interruption-and-rechallenge-with-clinical-outcomes-in-patients-with-rifampicin-resistant-tuberculosis-in-south-africa-2018-22-an-observational-cohort-study.md) (DOI: 10.1016/S2214-109X(25)00489-9)
- [Genomic analysis of an optrA-carrying plasmid linked to linezolid resistance in Enterococcus faeca](https://medichelpline.com/clinical-feed/pubmed-42678601.md) (DOI: 10.1007/s10096-026-05657-4)
- [Integrative conjugative element in Streptococcus pyogenes carries a cfr-like gene linked to linezo](https://medichelpline.com/clinical-feed/pubmed-42627159.md) (DOI: 10.1128/msphere.00277-26)
- [Fresh fruit surfaces as reservoirs of multidrug-resistant, biofilm-forming Enterococcus faecalis](https://medichelpline.com/clinical-feed/plos-one-3-fresh-fruit-surface-a-potential-source-for-multidrug-resistant-biofilm-forming.md)
- [ODN-39M and LALF32-51 as nasal adjuvants to boost immune responses to rAg85B](https://medichelpline.com/clinical-feed/biorxiv-0-synthetic-adjuvants-to-potentiate-the-immune-response-against-rag85b-by-nasal.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.